-
EHDN 2026 Part 1: What’s next in the Huntington’s disease treatment pipeline?
9 min read
Latest News
-
Skyhawk’s drug trial takes flight in the US
4 min read
Skyhawk’s FALCON-HD trial has dosed the first participants in the US with the drug, SKY-0515. The once-daily pill targets two drivers of HD, but does it actually slow disease? That’s the big question this study hopes to answer.
-
Dimebon: disappointing in Alzheimer’s but might work in HD
3 min read
Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
-
Does HD cause brains to develop differently?
4 min read
Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
-
Is Huntington’s disease twice as common as we thought?
5 min read
New data suggest there may be twice as many people with HD symptoms as previously thought – and even more at risk
-
Two large HD observational studies – COHORT and Registry – merge to create ENROLL-HD
5 min read
Merger of two major Huntington’s Disease observational trials creates ENROLL-HD
-
Huntexil for symptoms of Huntington's disease: where are we now?
6 min read
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
-
Minocycline: the end of the road?
5 min read
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
-
TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients
7 min read
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
